Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Abbott Laboratories (ABT)
Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,198,272
  • Shares Outstanding, K 1,738,947
  • Annual Sales, $ 43,653 M
  • Annual Income, $ 6,933 M
  • 60-Month Beta 0.67
  • Price/Sales 4.10
  • Price/Cash Flow 14.08
  • Price/Book 4.80
Trade ABT with:

Options Overview Details

View History
  • Implied Volatility 17.85% ( -1.29%)
  • Historical Volatility 14.15%
  • IV Percentile 2%
  • IV Rank 3.92%
  • IV High 33.84% on 09/27/22
  • IV Low 17.20% on 04/21/23
  • Put/Call Vol Ratio 0.42
  • Today's Volume 13,352
  • Volume Avg (30-Day) 7,600
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 182,136
  • Open Int (30-Day) 217,936

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 1.04
  • Number of Estimates 9
  • High Estimate 1.09
  • Low Estimate 1.02
  • Prior Year 1.43
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.38 +3.81%
on 05/31/23
112.95 -7.75%
on 05/03/23
-7.30 (-6.55%)
since 05/02/23
3-Month
96.39 +8.10%
on 03/13/23
112.95 -7.75%
on 05/03/23
+1.57 (+1.53%)
since 03/02/23
52-Week
93.25 +11.74%
on 10/21/22
118.23 -11.87%
on 06/06/22
-13.31 (-11.33%)
since 06/02/22

Most Recent Stories

More News
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

Recent troubles won't stop these companies' long-term trajectories.

ABT : 104.20 (+1.34%)
JNJ : 156.97 (+1.57%)
Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign

Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to work together...

ABT : 104.20 (+1.34%)
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning

ISRG : 312.18 (+0.53%)
ABT : 104.20 (+1.34%)
BAC : 28.71 (+3.35%)
BDX : 251.79 (+1.48%)
BSX : 51.82 (+0.62%)
INTU : 430.49 (+1.98%)
JPM : 140.47 (+2.10%)
MDT : 83.76 (+1.22%)
MBOT : 1.7600 (-18.52%)
SYK : 278.30 (-0.10%)
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations

/PRNewswire/ -- New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF...

ABT : 104.20 (+1.34%)
Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

/PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a...

ABT : 104.20 (+1.34%)
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm

/PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter,...

ABT : 104.20 (+1.34%)
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

/PRNewswire/ -- Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA)...

ABT : 104.20 (+1.34%)
Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options

FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic back pain...

ABT : 104.20 (+1.34%)
Best Medical Stock Investors Should Buy in a Recession

Despite the cooling down of inflation, a Fed rate cut is not in sight. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the...

ABT : 104.20 (+1.34%)
SNN : 30.24 (+1.04%)
UTMD : 95.00 (+1.15%)
ZBH : 129.81 (+1.92%)
Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

ABT : 104.20 (+1.34%)
JNJ : 156.97 (+1.57%)
ISRG : 312.18 (+0.53%)
EW : 85.34 (+0.13%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 106.50
2nd Resistance Point 105.50
1st Resistance Point 104.85
Last Price 104.20
1st Support Level 103.20
2nd Support Level 102.20
3rd Support Level 101.55

See More

52-Week High 118.23
Fibonacci 61.8% 108.69
Fibonacci 50% 105.74
Last Price 104.20
Fibonacci 38.2% 102.79
52-Week Low 93.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar